Expert consensus on surgical management of unilateral Wilms tumor (2025) Authors: Dongsheng Wang, Xiaofeng Chang, Xin Liu, Hongting Lu, Lei Zhang, Jinhu Wang, Jinghao Yan, Hongquan Geng, Dawei He, Zhongrong Li, Kai Li, Yong Li, Zhibao Lv, Jian Shen, HongCheng Song, Daxing Tang, Jian Wang, Shan Wang, Yeming Wu, Jianguo Zhang, Shouhua Zhang, Weiping Zhang, Qiang Zhao, Dapeng Jiang, Yi Yang, Huanmin Wang Published: 2026 ABSTRACT AbstractWilms tumor (WT) is the most common primary malignant renal tumor in children. Currently, there is no unified consensus regarding surgical management of WT. This is particularly so in complex cases where tumors are large, where there is invasion of adjacent organs, for nephron-sparing procedures, and for lymph node biopsy. Non-standardized surgical procedures can lead to tumor recurrence and progression; this is of increasing clinical concern. Standardizing the surgical approach and protocols for WT is therefore of great importance to improving treatment outcomes and patient prognosis. To better guide clinical practice, the Oncology Surgery Group and Urology Surgery Group of Pediatric Surgery Branch of the Chinese Medical Associationhave formulated this expert consensus. Based on previous clinical research findings and existing guidelines, the consensus provides specific recommendations for surgical approach and for decision-making.Keywords: Medical Oncology, Pediatrics Introduction Nephroblastoma, also known as Wilms tumor (WT), is the most common primary malignant renal tumor in children. Outcomes for WT patients have significantly improved as a result of detailed studies covering pathogenesis, molecular diagnosis, treatment, and prognosis. Indeed, Chinese experts have previously published a series of recommendations and consensus guidelines regarding the diagnosis and treatment of WT.1,3 However, there is currently no consensus regarding either surgical principles or strategy for surgical technique selection for WT; this is especially so in complex cases (e.g., massive tumors or those invading adjacent organs). Moreover, there is no consensus for procedures which encompass surgical decision-making, nephron-sparing surgery (NSS), and lymph node sampling. Furthermore, surgeons performing WT resections come from diverse professional backgrounds, which may contribute to variations in practice. Consequently, complications resulting from non-standardized surgical procedures, including tumor recurrence and iatrogenic progression, have become a matter of increasing clinical concern.4 Further standardization of WT surgical methodology and protocols is of great significance for improving treatment efficacy and patient prognosis. To this end, we convened an expert panel to formulate this consensus. Evidence evaluation and grading were conducted using the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (see table 1).5 Table 1Levels of clinical evidence and grades of recommendation used by Oxford University Centre for Evidence-Based MedicineGrade of recommendationLevel of evidenceSource of evidence (therapeutic studies)AIaSR (with homogeneity) of RCTsIbSR (with homogeneity) of RCTsIcAll or none case seriesBIIaSR (with homogeneity) of cohort studiesIIbIndividual cohort study (including low-quality RCT; e.g., <80% follow-up)IIc“Outcomes” researchIIIaSR (with homogeneity) of case-control studiesIIIbIndividual case-control studyCIVCase series (and poor-quality cohort and case-control studies)DVExpert opinion without explicit critical appraisal, or based on physiology, bench research, or ‘first principles’RCT, randomized controlled trial; SR, systematic review. Levels of clinical evidence and grades of recommendation used by Oxford University Centre for Evidence-Based Medicine RCT, randomized controlled trial; SR, systematic review. The fundamental principles for WT surgery, established by William Edwards Ladd, emphasize safe resection with accurate staging (via adequate lymph node sampling), prioritizing renal artery ligation, and avoiding maneuvers that cause progression. These basic principles are still applicable to both traditional open and minimally invasive surgery (MIS). Based on previous clinical research and guidelines, this consensus provides guidance on surgical detail and plan selection. Methods Consensus formulation process and methodology Target audience and scope The target population of this consensus is children with unilateral WT aged 0–18 years. The intended users include practicing physicians involved in WT diagnosis and treatment. This includes pediatric surgeons, pediatric oncologists, relevant medical technicians, and researchers. Analysis of clinical questions and evidence retrieval Based on the finally agreed clinical questions, an evidence-based search was conducted across major Chinese and English databases (e.g., CNKI, PubMed, Cochrane Library). The search focused on systematic reviews, randomized controlled trials, cohort studies, and guidelines published in recent years, with the scope expanded when necessary to ensure comprehensive coverage of the evidence. Evidence assessment and formation of recommendations This consensus includes 17 clinical questions (see table 2). The formulation team, organized by the Oncology Surgery Group and Urology Surgery Group of Pediatric Surgery Branch of the Chinese Medical Association, collected a list of surgical questions related to unilateral WT diagnosis and treatment through clinical frontline discussions. The consensus formulation team evaluated these using the Delphi method to form initial recommendations. Recommendations were finalized after iterative rounds of discussion and revision by a panel of national experts (consistent with the author list). Table 2List of the 17 clinical questions addressed in this consensusNo.Clinical questions1Upfront surgery compared with preoperative chemotherapy2Indications and contraindications for preoperative biopsy3Selection of surgical incision4Management of renal vessels5Lymph node sampling6Collecting system/ureter invasion and ureteral stump7Preservation of the adrenal gland8Organ preservation9Tumor thrombus: classification and management10Management of preoperative tumor rupture11Management of recurrent Wilms tumor12Management of metastatic lesions13Nephron-sparing surgery for pediatric Wilms tumors14Minimally invasive surgery for pediatric Wilms tumors15Management of Wilms tumors in horseshoe kidney16Management of renal tumors in special populations17Postoperative follow-up protocol List of the 17 clinical questions addressed in this consensus Results and recommendations Upfront surgery compared with preoperative chemotherapy Surgery is the core link in the multidisciplinary treatment of WT. Consequently, a perioperative multidisciplinary assessment should be strictly implemented for every patient. This assessment encompasses: suitability for tumor resection along with comorbidities, surgical strategy, anesthesia risk, adequacy of blood preparation, intraoperative monitoring, establishment of reliable venous access, level of postoperative care or monitoring, and postoperative pain management. According to a protocol from the Chinese Children’s Cancer Group (CCCG), surgery is recommended for tumors assessed preoperatively as amenable to complete resection. However, for cases presenting with significant surgical difficulty or high risk, neoadjuvant chemotherapy followed by surgery is advised.1 3 Therefore, this consensus incorporates the National Comprehensive Cancer Network (NCCN) guidelines and protocols.6 Whether immediate surgery or surgery after neoadjuvant chemotherapy is chosen, the goal is complete tumor resection. For unilateral WT, the goal of surgery is complete local resection of the lesion, accurate lymph node staging, and comprehensive histological evaluation, while minimizing complications.7 In the series of studies conducted by the Children’s Oncology Group (COG), the overall complication rate for immediate surgery has decreased. However, the risk of surgical complications and intraoperative tumor rupture increases with tumor size or the presence of intravascular extension.8 Furthermore, the risk of intraoperative tumor rupture is significantly higher for tumors with a diameter greater than 15 cm. CT or MRI is helpful to identify risk features, such as local invasion, vascular involvement, and lymph node metastasis.9 However, the sensitivity and specificity of preoperative CT for detecting tumor rupture are relatively low.10 Studies have shown that WT1 gene mutations can simultaneously affect embryonic renal development and the embryonic origin of renal cancer.11 For these patients, the risk of developing renal failure is high, so immediate surgery is generally not recommended. Typical clinical manifestations can identify these syndromic patients; genetic testing (e.g., whole exome sequencing, gene chips) is the gold standard for diagnosis. (Recommendation 1) Immediate radical nephrectomy is recommended. If the surgical risk is high or the tumor is initially unresectable, preoperative chemotherapy followed by surgery is recommended (evidence level II a, recommendation grade B). If adhering to the International Society of Pediatric Oncology (SIOP) protocol, this recommendation does not need to be considered. (Recommendation 2) When adhering to the COG protocol, neoadjuvant chemotherapy followed by surgery is recommended for tumors assessed as unresectable (refer to recommendation 3) or to facilitate NSS through tumor volume reduction. With respect to indications for NSS and technical considerations, see the NSS for pediatric Wilms tumors section (evidence level II a, recommendation grade B). (Recommendation 3) Immediate surgery is not recommended in the following circumstances: (1) confirmed germline WT1 mutation; (2) high anesthetic risk, such as severe pulmonary disease, tumor embolism, or a massive abdominal tumor causing pulmonary dysfunction; (3) the surgeon assesses that resection would result in severe complications, death, tumor migration, or retention of residual tumor; (4) solitary kidney; (5) tumor thrombus above the level of the hepatic veins. See Section Tumor thrombus:classification and management for management principles of thrombus (evidence level II a, recommendation grade B). Indications and contraindications for preoperative biopsy While the incidence of complications associated with renal biopsy is currently considered to be very low, only approximately 10% of patients derive clinical benefit from the procedure; the resulting benefit-to-risk ratio is therefore low.12 Furthermore, to avoid severe injury, percutaneous cutting needle biopsy (PCNB) is recommended over open biopsy.13 The SIOP protocol advises against routine biopsy, positing that even if the postoperative pathological diagnosis reveals a different tumor type, short-term preoperative therapy (consisting of 4 weeks of vincristine and actinomycin D, with the addition of doxorubicin for metastatic patients) will not compromise the formulation of postoperative treatment strategies or therapeutic efficacy. Similarly, the COG discourages initial biopsy, recommending instead that immediate radical nephrectomy be performed whenever feasible. This is followed by adjuvant therapy based on tissue diagnosis, stage, and biological characteristics. Since biopsy may lead to local tumor spread, COG recommends upgrading biopsy patients to stage III. The latest NCCN guidelines recommend biopsy for patients meeting delayed resection criteria to confirm tissue type and obtain molecular biological markers to guide treatment. Furthermore, percutaneous biopsy carries a risk of associated complications, including pain, a decrease in hemoglobin levels, incidental emergency nephrectomy (due to tumor rupture), and needle tract seeding. (Recommendation 4) Percutaneous biopsy is generally not recommended (evidence level IIa, recommendation grade B). This is particularly so in the following circumstances: (1) localized renal tumors in neonates or infants aged 3 months or younger where tumors are typically congenital mesoblastic nephroma (CMN), which is mostly curable by surgery alone; (2) for completely cystic tumors, these may represent cystic partially differentiated nephroblastoma or cystic nephroma. Biopsy of the cyst wall cannot provide sufficient tissue for differential diagnosis, and preoperative chemotherapy does not induce tumor shrinkage; (3) When imaging reveals renal nodular lesions associated with nephroblastomatosis or nephrogenic rests that are difficult to distinguish, tissue obtained via needle biopsy is insufficient for differential diagnosis (evidence level III, recommendation grade B). (Recommendation 5) Percutaneous biopsy is recommended in the following circumstances13: (1) if unclear that the mass originates from the kidney; (2) suspected benign disease, especially infection-related tumors, such as renal abscess or xanthogranulomatous pyelonephritis; (3) imaging examination highly suggestive of non-WT; (4) stage IV pediatric patients and patients >10 years of age (evidence level III a, recommendation grade B). Selection of surgical incision A transabdominal or thoracoabdominal incision is recommended. The incision must be of sufficient size to prevent tumor rupture caused by compression.1 3 6 14 A subcostal oblique incision may be considered; this approach facilitates exposure of the upper pole of the tumor while avoiding the surgical trauma associated with a thoracotomy. (Recommendation 6) A transverse abdominal incision is recommended as the surgical approach. For massive tumors, a thoracoabdominal incision can minimize tumor rupture (evidence level III a, recommendation grade B). Management of renal vessels Intraoperatively, priority should be given to ligation of the renal pedicle vessels to prevent hematogenous dissemination caused by tumor manipulation. If the renal artery and vein can be rapidly isolated and secured, there is no strict requirement regarding the sequence of ligation, although ligation of the artery first is generally preferred. However, in cases with massive tumors where the renal hilum is inaccessible, the tumor may be mobilized first, followed by management of the renal pedicle as the final step; throughout this process, excessive tumor compression must be strictly avoided. (Recommendation 7) Ligation of the renal pedicle vessels should be prioritized before nephrectomy. However, in cases of massive tumors where the renal hilum cannot be exposed, the tumor-bearing kidney may be mobilized first, and the renal pedicle vessels managed last (evidence level IIIa, recommendation grade B). Lymph node sampling The quality of lymph node sampling directly impacts staging accuracy and treatment decision-making. Inadequate lymph node sampling and incorrect staging are associated with increased local recurrence and decreased long-term survival. However, lymph node dissection does not improve long-term prognosis and has therefore been replaced by lymph node sampling.15 In patients with 1p or 16q loss of heterozygosity (LOH), a failure to perform lymph node biopsy or lymph node negativity is associated with lower event-free survival (EFS). In 1p and 16q LOH-positive WT patients, EFS is lower in those with positive lymph nodes.16 In WTs with favorable histology (FH), positive lymph node rate correlates with disease prognosis; a lower LNR is associated with better survival.17 Lymph node yield positively correlates with patient age and tumor size. Preoperative imaging of lymph node metastasis is limited. CT and MRI demonstrate comparable performance and are characterized by high specificity but low sensitivity. Therefore, lymph node size on imaging cannot serve as the sole basis for determining nodal positivity.18 Intraoperatively, surgeons are often unable to accurately assess nodal involvement, and lymph nodes in potential metastatic regions should be biopsied regardless of their gross appearance. A common site of metastasis is the aortocaval lymph nodes.19 Open surgery is conducive to lymph node biopsy, whereas laparoscopic surgery makes whole-process lymph node biopsy difficult and should only be performed for selected patients at experienced medical centers.20 21 In the SIOP 2001 trial, the proportion of lymph node biopsies successfully performed by laparoscopy was 15/24, with a positivity rate of 5/15.22 While no consensus has been reached regarding the minimum number of lymph nodes to be retrieved from specific locations, suspicious lymph nodes should be sampled from the renal hilum, aortocaval region, para-aortic region, aortic bifurcation, ipsilateral iliac vessels, origin of the celiac trunk, and the superior mesenteric artery (SMA). In WTs with FH, the number of lymph nodes sampled should be 6–10 to maintain a false-negative rate below 10%.23 Cooperation between surgeons and pathologists to obtain more than seven lymph nodes is feasible24; this improves biopsy positivity rates.25 Submitting the tumor and peritumoral lymph nodes en bloc for pathological examination, without separation, is prone to missed diagnosis.26 In laparoscopic-assisted surgery, performing lymph node sampling prior to transection of the renal vessels and tumor resection facilitates lymph node identification and subsequent biopsy.27 Beyond preventing lymphatic leakage, the surgical approach should involve novel methods for sentinel lymph node identification, based on a comprehensive understanding of renal lymphatic drainage patterns, to improve the positivity rate of lymph node sampling.28 (Recommendation 8) Adequate lymph node sampling should be performed intraoperatively. Open surgery facilitates improved quality of lymph node sampling (evidence level IIIa, recommendation grade B). (Recommendation 9) In addition to sampling lymph nodes from the ipsilateral renal hilum, iliac vessels, origin of the celiac trunk, and SMA, the procedure should include paracaval lymph nodes for right-sided tumors and para-aortic lymph nodes for left-sided tumors. Sampling more than seven lymph nodes facilitates increased positivity rates. Surgical records should clearly document biopsy sites (evidence level IIIa, recommendation grade B). Collecting system or ureter invasion and ureteral stump Involvement of the collecting system in WT patients is uncommon, occurring in approximately 2% of unilateral cases. Preoperative hematuria, hydronephrosis, or focal filling defects on imaging may suggest collecting system invasion. Careful intraoperative assessment of tumor extension is required; the ureter should be transected distal to tumor-free margins. Intraoperative ultrasound or endoscopic evaluation may be used when necessary. If preoperative imaging demonstrates tumor thrombus extending into the bladder, neoadjuvant chemotherapy may be considered to reduce tumor burden prior to surgical resection. Whenever feasible, the ureter should be ligated as close to the bladder as possible.6 29 (Recommendation 10) The distal ureteral margin should be below the level of the iliac vessel bifurcation, with ligation as close to the bladder as possible. If the ureteral wall is invaded by tumor, the ureter should be transected distal to the segment involved (evidence level IIa, recommendation strength B). Preservation of the adrenal gland Although WTs may adhere to surrounding tissues, true adrenal invasion is rare. Routine adrenalectomy is therefore not recommended unless direct invasion is present.6 14 COG studies report ipsilateral adrenal involvement in approximately 4.4% of cases, with no significant impact of adrenalectomy on overall or EFS.30 (Recommendation 11) If the adrenal gland is invaded, complete resection of the adrenal tissue involved is recommended. In unilateral renal tumors, adrenal preservation is appropriate even for upper-pole tumors, provided that the gland can be safely separated from the tumor (evidence level IIIa, recommendation strength B). Organ preservation Most WTs do not invade adjacent organs and are highly chemosensitive. Once complete tumor nephrectomy is achieved, unnecessary resection of surrounding organs should be avoided, as such procedures do not improve survival and increase postoperative morbidity. Limited resection may be considered for focal adherence. In cases where extensive invasion is suspected, neoadjuvant chemotherapy may reduce tumor size and surgical morbidity.6 (Recommendation 12) On the assumption of complete tumor resection, injury to adjacent normal tissues should be minimized. In cases where extensive invasion is suspected, preoperative neoadjuvant chemotherapy may be administered to maximize organ preservation (evidence level IIIa, recommendation strength B). Tumor thrombus: classification and management Approximately 10% of patients with WTs present with intravascular tumor thrombus involving the renal vein and/or inferior vena cava (IVC); extension into the right atrium occurs in 1%–3% of cases. Modern ultrasonography and contrast-enhanced CT allow reliable detection and preoperative assessment. COG data indicate that nearly 80% of patients demonstrate thrombus regression following neoadjuvant chemotherapy; preoperative chemotherapy is recommended for thrombi extending above the hepatic veins. Moreover, SIOP recommends neoadjuvant chemotherapy for all patients with tumor thrombus. While chemotherapy may reduce thrombus burden and embolic risk, it may also increase thrombus adherence to the vessel wall in some cases. Tumor thrombi are classified according to the Daum system (stages I–IV) based on their cephalad extension.31 Surgical management should be tailored to thrombus location. For thrombi confined to the renal vein or infradiaphragmatic IVC, en bloc removal is generally feasible following appropriate vascular control. For thrombi extending above the hepatic veins or into the atrium, cardiopulmonary bypass is usually required, and management should involve multidisciplinary collaboration. Intraoperative echocardiography may assist in real-time assessment of thrombus extent and dynamics.32 33 The role of perioperative anticoagulation remains controversial. Available evidence suggests no survival benefit in asymptomatic patients, while anticoagulation may increase bleeding risk.34 35 (Recommendation 13) Preoperative neoadjuvant chemotherapy is recommended for patients with tumor thrombus extending above the hepatic veins or when primary surgical resection is considered difficult (evidence level IIa, recommendation strength B). (Recommendation 14) Management of tumor thrombus should be individualized according to thrombus location, with the goal of complete removal while minimizing embolic and thrombotic complications. Multidisciplinary collaboration should be considered when appropriate (evidence level IIa, recommendation strength B). (Recommendation 15) Operative reports should document the presence, location, and extent of tumor thrombus, including any adherence to the vessel wall and the presence of residual thrombus (evidence level III, recommendation strength B). (Recommendation 16) Postoperative anticoagulation should be individualized based on intraoperative findings and multidisciplinary discussion (evidence level IIIa, recommendation strength B). Management of preoperative tumor rupture In the SIOP study, patients with tumor rupture accounted for 10.2% (173/1702) of patients enrolled. A study from China reported a preoperative tumor rupture rate of 8.0% (45/565), with the majority being spontaneous.36 Since pathological examination cannot definitively determine whether tumor rupture occurred prior to the initiation of neoadjuvant chemotherapy, patients with preoperative rupture enrolled in SIOP studies, who consequently received reduced intensity chemotherapy (chemotherapy dose reduction), may have an increased risk of local recurrence. Currently, no definitive conclusion has been reached regarding the clinical significance of this risk. CT evidence of a large volume of intraperitoneal fluid is a risk factor for preoperative tumor rupture. Furthermore, increased peritumoral fat density and retroperitoneal fluid accumulation are also suggestive of tumor rupture. However, CT has limited specificity and sensitivity for detecting preoperative tumor rupture.10 Studies have also found no significant difference in tumor size between those with and without preoperative rupture.36 Emergency surgery is indicated for patients with preoperative spontaneous or traumatic tumor rupture presenting with hemodynamic instability and unstable vital signs. Currently, emergency angioembolization has been reported for the management of ruptured WT.36 37 (Recommendation 17) For patients with confirmed preoperative spontaneous or traumatic tumor rupture accompanied by hemodynamic instability or unstable vital signs, emergency intervention (e.g., nephrectomy or angioembolization) is indicated. For hemodynamically stable patients with tumor rupture, surgery may be deferred until after chemotherapy (evidence level IV, recommendation grade C). Management of recurrent WT The prognosis for recurrent WT remains challenging, with survival rates significantly lower than those of primary disease. Comprehensive and compassionate communication with parents is therefore essential prior to reinitiating treatment. Recurrent WT is classified based on the initial chemotherapy regimen and histopathological type: Standard risk: non-anaplastic histology and recurrence after treatment with vincristine and actinomycin D only. Survival rate is 70%–80%. Treatment involves surgery, radiotherapy, and chemotherapy, requiring a four-drug combination chemotherapy regimen (a combination of doxorubicin and/or cyclophosphamide with carboplatin and/or etoposide). Standard risk: non-anaplastic histology and recurrence after treatment with vincristine and actinomycin D only. Survival rate is 70%–80%. Treatment involves surgery, radiotherapy, and chemotherapy, requiring a four-drug combination chemotherapy regimen (a combination of doxorubicin and/or cyclophosphamide with carboplatin and/or etoposide). High risk: non-anaplastic histology and recurrence after treatment with three or more drugs. Survival rate is 40%–50%. Treatment involves chemotherapy, surgery, and/or radiotherapy. Induction chemotherapy with a combination of etoposide and carboplatin plus either ifosfamide or cyclophosphamide is used. To reduce the risk of ifosfamide-related nephrotoxicity, alternating cycles of cyclophosphamide and ifosfamide are recommended. High risk: non-anaplastic histology and recurrence after treatment with three or more drugs. Survival rate is 40%–50%. Treatment involves chemotherapy, surgery, and/or radiotherapy. Induction chemotherapy with a combination of etoposide and carboplatin plus either ifosfamide or cyclophosphamide is used. To reduce the risk of ifosfamide-related nephrotoxicity, alternating cycles of cyclophosphamide and ifosfamide are recommended. Very high risk: anaplastic or blastemal-type WT. Survival rate is approximately 10%. Treatment involves chemotherapy, surgery, and/or radiotherapy. Consideration of camptothecin analogs (such as irinotecan or topotecan) or novel agents is recommended. Very high risk: anaplastic or blastemal-type WT. Survival rate is approximately 10%. Treatment involves chemotherapy, surgery, and/or radiotherapy. Consideration of camptothecin analogs (such as irinotecan or topotecan) or novel agents is recommended. Recurrence within the first year of surgery indicates poor prognosis. Surgery is recommended whenever feasible for radical resection, or to evaluate pathological response, if a reduction in recurrent tumor burden is confirmed after chemotherapy. This is regardless of histological type or risk stratification. Radiotherapy should also be administered to sites that did not receive initial irradiation. However, formulating standard recommendations for previously irradiated sites is difficult, and consultation with a radiation oncology specialist within a multidisciplinary team (MDT) is advised. For first relapse, whether metastatic or local, most lesions are resectable. The general principle for managing recurrent WTs is: second-line chemotherapy is the preferred initial approach. However, for late-appearing (more than 2 years post surgery) isolated pulmonary nodules or central nervous system metastases, primary surgical intervention is suggested. Surgery is not recommended for metastatic lesions that progress during chemotherapy, unless solitary, where resection may be considered. If recurrence occurs within a previously irradiated field, surgery is the most effective treatment. For contralateral WT recurrence (metachronous WT), surgery by an experienced surgical team after tumor shrinkage with chemotherapy is recommended.38 (Recommendation 18) Second-line chemotherapy is the preferred initial treatment. Recurrence within the first year of surgery indicates a poor prognosis (evidence level III, recommendation strength B). (Recommendation 19) For first relapse, whether metastatic or local, most lesions are resectable. For late-appearing (more than 2 years post surgery) isolated pulmonary nodules or central nervous system metastases, primary surgical intervention is suggested. Surgery is not recommended for metastatic lesions that progress during chemotherapy. If recurrence occurs within a previously irradiated field, surgery is the most effective treatment (evidence level III, recommendation strength B). Management of metastatic lesions Pulmonary metastases Preoperative chemotherapy comprises a 6-week course of combination chemotherapy with vincristine, actinomycin D, and doxorubicin. Re-evaluation is performed following chemotherapy. Patients who achieve a complete response continue postoperative chemotherapy without pulmonary radiotherapy. For patients with residual pulmonary lesions, surgical resection of the metastatic lesions is performed when feasible, safe, and free from long-term complications. If complete resection is not possible, representative resectable nodules are removed to guide postoperative therapy. When pathologic assessment of the resected lesions reveals necrotic or non-viable tumor tissue, treatment follows the regimen for the localized tumor. When pathology shows viable metastatic tumor tissue, or when a biopsy cannot be obtained to determine the nature of the lesions, treatment is administered according to the stage IV protocol, based on the local tumor stage, histology, and whether pulmonary metastases were completely or incompletely resected.39 When chest CT shows a complete response, postoperative treatment follows the protocol for the localized tumor, and surveillance CT is performed every 8–12 weeks for 2 years. For residual or progressive nodules, re-resection is performed. If pathology shows only necrotic tissue with complete resection, no radiotherapy is given, whereas if viable tumor is present, radiotherapy is administered. If a biopsy cannot be obtained, treatment proceeds according to the histology of the localized tumor. For FH WT with isolated pulmonary metastasis, a 6-week course of combination chemotherapy with vincristine, actinomycin D, and doxorubicin is used. Patients whose pulmonary nodules show a complete response continue the same chemotherapy regimen without radiotherapy, whereas patients whose pulmonary nodules show no response at all, or who have LOH at 1p/16q, receive pulmonary radiotherapy and four courses of Regimen M.39 (Recommendation 20) Preoperative combination chemotherapy with vincristine, actinomycin D, and doxorubicin should be administered for pulmonary metastases; re-evaluation is required prior to nephrectomy (evidence level III, recommendation strength B). (Recommendation 21) The postoperative treatment plan for pulmonary metastases should be determined based on both the response of the pulmonary nodules to chemotherapy (including the number of nodules, presence of residual lesions, and presence of viable tumor tissue within the lesions) and the histopathology of the primary renal tumor (evidence level III, recommendation strength B). Liver metastases Liver metastases are primarily managed with chemotherapy and radiotherapy. Surgical resection (e.g., wedge resection) may be considered for isolated, persistent lesions after chemotherapy.39 (Recommendation 22) The management of liver metastases primarily relies on chemotherapy and radiotherapy. Isolated liver metastases may be treated with wedge resection following chemotherapy (evidence level IV, recommendation strength C). Intracranial metastases Brain metastases occur in approximately 1%–2% of patients with WTs and are associated with poor prognosis. Brain MRI is required for diagnosis in patients with neurological symptoms. Management typically involves multimodal therapy, including surgery, radiotherapy, and chemotherapy, and should be determined through multidisciplinary discussion.40 (Recommendation 23) WT patients presenting with neurological symptoms should undergo brain MRI to exclude intracranial metastases (evidence level IIa, recommendation strength B). (Recommendation 24) Management of intracranial metastases should be discussed within a MDT (evidence level IIa, recommendation strength B). Nephron-sparing surgery for pediatric WT NSS is not routinely recommended for unilateral WT, except in syndromic or bilateral cases. For unilateral disease, it requires strict patient selection, balancing renal preservation against recurrence risk. If considered, all of the following criteria must be met, and thorough preoperative communication with the patient’s parents is essential. (1) The tumor is located at one pole or the peripheral midportion of the kidney without invasion of surrounding organs. (2) Tumor volume at diagnosis is less than 300 mL. Smaller tumors have only a 2% probability of positive lymph nodes. (3) No preoperative tumor rupture (imaging signs of rupture include: peritumoral retroperitoneal fluid or hemorrhage, intra-abdominal hemorrhage, or tumor nodules, open biopsy-related or spontaneous rupture) and no intraoperative rupture. (4) Preoperative imaging shows no tumor within the renal pelvis. (5) No invasion of surrounding organs by the tumor. (6) No tumor thrombus in the renal vein or IVC. (7) No multifocal tumor lesions. (8) Negative surgical margins can be ensured. (9) The residual kidney has adequate function. (10) At least 66% of renal parenchyma is preserved while ensuring healthy margins, which helps mitigate postoperative hyperfiltration injury in the remnant kidney.41 If surgical margins are positive after NSS (the finding of nephrogenic rests at the resection margin is not considered a positive margin), postoperative radiotherapy is required to prevent local recurrence. If lymph nodes are positive, postoperative radiotherapy should be added without the need for complete nephrectomy. If the pathology is unfavorable (e.g., diffuse anaplasia), re-operation for complete nephrectomy followed by radiotherapy is necessary. If the resected specimen contains nephroblastomatosis or nephrogenic rests, indicating a risk of metachronous WT in the remnant or contralateral kidney, close follow-up is required. (Recommendation 25) NSS is not routinely recommended (evidence level III, recommendation strength B). (Recommendation 26) If NSS is performed, specific criteria must be met, balancing preservation of renal function against tumor recurrence risk. Thorough preoperative communication with the patient’s parents is required (evidence level IV, recommendation strength C) MIS for pediatric WT MIS remains controversial for both nephrectomy and NSS. Although some studies indicate that laparoscopic or robot-assisted transabdominal WT resection can achieve comparable therapeutic outcomes to traditional open surgery in experienced centers and highly selected cases (small tumor volume, postchemotherapy status, and polar or marginal tumor location), open surgery is still recommended. MIS must adhere to oncologic principles, including standard lymph node biopsy. Ideal candidates have tumors <300 mL, centrally located, and surrounded by normal parenchyma. The extraction incision must allow intact removal to prevent rupture. If NSS is indicated, when NSS is performed, active conversion to open surgery should be undertaken when necessary. Contraindications for MIS include: (1) tumor infiltration into extrarenal structures or extension beyond the ipsilateral spinal margin; (2) tumor thrombus in the renal vein or IVC; (3) peripheral tumor location where NSS is not feasible; (4) poor response of WT to chemotherapy (risk of tumor rupture); (5) lack of surgeon experience in minimally invasive renal tumor resection.41 Conversion from minimally invasive to open surgery of nephrectomy or NSS should not be considered a complication or failure but rather a cautious and judicious decision for the benefit of the patient. The surgical goal should be complete negative margins and adequate lymph node sampling. If this cannot be achieved through minimally invasive methods, an open approach should be adopted. (Recommendation 27) Open surgery is the recommended approach (evidence level III, recommendation strength B). (Recommendation 28) If minimally invasive nephrectomy or NSS is performed, oncologic surgical principles must still be followed. The goal is complete negative margins and adequate lymph node sampling. Conversion to open surgery should not be viewed as a complication or failure (evidence level III, recommendation strength B). Management of WTs in horseshoe kidney A WT arising in a horseshoe kidney is rare. Comprehensive preoperative imaging is essential to define tumor location, vascular anatomy, and collecting system configuration.42 Surgical management should be tailored according to tumor location and extent.43,45 To reduce intraoperative risk while maximizing renal function preservation, neoadjuvant chemotherapy plays an important role in the treatment of these patients.46 47 Therefore, preoperative neoadjuvant chemotherapy is recommended for this group of patients. For unilateral disease, complete resection of the affected renal moiety and isthmus is recommended. For bilateral disease, management should follow bilateral WT protocols, with NSS performed after neoadjuvant chemotherapy. (Recommendation 29) Comprehensive preoperative imaging evaluation is recommended for a WT arising in a horseshoe kidney (evidence level IIIb, recommendation strength B). (Recommendation 30) For unilateral tumors, complete resection of the affected renal unit and isthmus is recommended. For bilateral disease, treatment should follow bilateral WT protocols (evidence level IIIb, recommendation strength B). Management of renal tumors in special populations Infants younger than 6 months Immediate surgical resection is generally recommended for solid renal tumors in infants younger than 6 months. CMN is typically managed with surgery alone, whereas malignant rhabdoid tumor requires intensive chemotherapy. Infants with WTs meeting low-risk criteria do not require adjuvant chemotherapy. (Recommendation 31) For unilateral renal tumors in infants younger than 6 months, immediate radical nephrectomy is recommended (evidence level IIIa, recommendation strength B). Children older than 10 years In children older than 10 years, renal cell carcinoma should be strongly suspected. For resectable disease, primary surgical resection is recommended. In cases of unresectable disease or distant metastasis, percutaneous biopsy should be performed to establish diagnosis and guide subsequent treatment. (Recommendation 32) Renal tumors in children older than 10 years should raise suspicion for renal cell carcinoma. Management should be guided by resectability and histopathological findings (evidence level IIIa, recommendation strength B). (Recommendation 33) NSS may be considered in selected patients following multidisciplinary discussion (evidence level IIIb, recommendation strength B). Postoperative follow-up protocol For children who have completed treatment for WT, post-treatment surveillance relies primarily on imaging studies, including CT, MRI, ultrasound, or chest X-ray. (Recommendation 34) Follow-up evaluations should be performed every 3 months during the first 1–2 years after completion of therapy and every 6 months during years 3–4 (evidence level IIIa, recommendation grade B). This article is a full English translation and secondary publication of the Chinese Expert Consensus entitled Expert Consensus on Surgical Management of Unilateral Wilms Tumor (2025), which was first published in the Chinese Journal of Clinical Pediatric Surgery. Publication of this translated version has been approved by the authors and the original publisher. The content of this article faithfully reflects the original publication without substantive modification. The original article should be cited as follows: Oncology Surgery Group and Urology Group of Pediatric Surgery Branch of the Chinese Medical Association. Chinese expert consensus on surgical management of unilateral Wilms tumor[J]. J Clin Ped Sur, 2025, 24(10): 905-915. DOI: 10.3760/cma.j.cn101785-202507051-002 Footnotes Patient consent for publication: Not applicable. Ethics approval: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Data availability statement Data sharing not applicable as no datasets were generated and/or analyzed for this study. References Associated Data Data Availability Statement Data sharing not applicable as no datasets were generated and/or analyzed for this study.